The Plaintiff, Akebia Therapeutics Inc. (“Akebia”), brought a motion requesting that the Court vacate the Defendant’s, Fibrogen Inc. (“Fibrogen”), designation of confidentiality over the entirety of two fact witness statements. The Court granted the motion on the basis that Fibrogen’s confidentiality designations were contrary to the terms of the Confidentiality Agreement between the parties.

Vincent Lam was a co-founder and former CEO of Ark Platforms Inc., which developed and marketed map-based project management software under the name “Arkit.”

This was an application seeking to vary the records of the Canadian Patent Office relating to the named inventors of Patent No. 2,508,339 [the ‘339 Patent].

This was a successful motion for leave to intervene on a default judgment motion.

NCS Multistage (NCS) appealed two Orders denying its request, on the eve of trial, to amend its pleading to: (a) include a remedy of a constructive trust; and, (b) allege that the patent infringement at issue had started earlier than originally claimed and to compel production of certain technical drawings from this earlier period. NCS’s appeal was dismissed.

This is a judicial review of the Copyright Board (the “Board”)’s decision respecting the quantum of royalty rates payable under Tariff for the Retransmission of Distant Television Signals, 2014-2018.

The Federal Court of Appeal upheld Seedlings Life Science Ventures v Pfizer Canada, 2020 FC 1, that found patent claims of an apparatus and method for rapid autoinjection (the ‘935 Patent) invalid for overbreadth, certain claims invalid for anticipation and obviousness, and not infringed (¶4, 6), and set aside the Federal Court’s conclusion that claims for an accounting of profits would be disallowed from licensees (¶77-81).

The Federal Court of Appeal dismissed an appeal of a Federal Court judgment (Seedlings Life Science Ventures v Pfizer, 2019 FC 1396 (FC Reasons)), that admitted into evidence certain documents produced as business records related to remedies during examination for discovery of a witness in a patent infringement trial because it determined the issue was moot (FCA Reasons, ¶1,6).

DeepRoot brought patent infringement action alleging that GreenBlue’s “RootSpace” product infringes various claims of their Patents number 2,552,348 (348 Patent) and number 2,829,599 (599 Patent). The Patents related to a subsurface structural cell system that supports the hardscape (e.g. sidewalk), enables stormwater retention and filtration as well as allowing tree roots to grow in uncompacted soil.

In the underlying simplified action, Blacklock claimed that Parks Canada had copied, distributed and accessed articles contrary to the Copyright Act. The action was one of 13 actions brought against various governmental departments, but the remaining 12 actions were on hold pending the outcome of the Parks Canada dispute.